Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cumberland Pharmaceuticals (CPIX) Current Deferred Revenue: 2009-2010

  • Cumberland Pharmaceuticals' Current Deferred Revenue rose 41.67% to $85.0 billion in Q4 2010 from the same period last year, while for Dec 2010 it was $85.0 billion, marking a year-over-year increase of 41.67%. This contributed to the annual value of $85.0 billion for FY2010, which is 41.67% up from last year.
  • Cumberland Pharmaceuticals' Current Deferred Revenue amounted to $85.0 billion in Q4 2010, which was up 41.67% from $60.0 billion recorded in Q4 2009.
  • In the past 5 years, Cumberland Pharmaceuticals' Current Deferred Revenue ranged from a high of $85.0 billion in Q4 2010 and a low of $60.0 billion during Q4 2009.
  • Over the past 2 years, Cumberland Pharmaceuticals' median Current Deferred Revenue value was $72.5 billion (recorded in 2009), while the average stood at $72.5 billion.
  • Data for Cumberland Pharmaceuticals' Current Deferred Revenue shows a peak YoY surged of 41.67% (in 2010) over the last 5 years.
  • Quarterly analysis of 2 years shows Cumberland Pharmaceuticals' Current Deferred Revenue stood at $60.0 billion in 2009, then spiked by 41.67% to $85.0 billion in 2010.